Cargando…
Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab
Cetuximab-based chemoimmunotherapy has been the standard of care for recurrent or metastatic squamous cell carcinoma of the head and neck (r/m SCCHN) for more than a decade. To date, no predictive or prognostic biomarkers have been established to further guide the systemic treatment with cetuximab-b...
Autores principales: | Pogorzelski, Michael, Hilser, Thomas, Ting, Saskia C., Kansy, Benjamin, Gauler, Thomas C., Stuschke, Martin, Schmid, Kurt W., Lang, Stephan, Grünwald, Viktor, Schuler, Martin, Kasper, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155676/ https://www.ncbi.nlm.nih.gov/pubmed/34055606 http://dx.doi.org/10.3389/fonc.2021.635096 |
Ejemplares similares
-
Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy
por: Pogorzelski, M, et al.
Publicado: (2014) -
Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007) -
Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015) -
Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020) -
A Phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC)
por: Ferris, Robert L, et al.
Publicado: (2015)